Nuo Therapeutics (CMXI) Growth Rates Comparisons to Medical Laboratories Industry, Sector, Market. Sales, Income, EPS
CSIMarket Company Name, Ticker, Industry, else..
 
Nuo Therapeutics, Inc.  (CMXI)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 

Nuo Therapeutics Growth Comparisons

Select each growth Category to receive further Information




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CMXI Revenue Growth Rate Comparisons Company Industry Sector S&P 500
Y / Y Revenue Growth (Q2 MRQ) - 11 % 9.81 % 3.91 %
Q / Q Revenue Growth (Q2 MRQ) - 2.47 % -1.24 % 0.22 %
Y / Y Revenue Growth (for 12 months ending Q2 TTM) - 7.72 % 16.17 % %
Sequential Revenue Growth (for 12 months ending Q2 TTM) - 2.65 % 2.55 % 0.91 %
Revenue 5 Year Average Growth - 15.97 % 11.73 % 10.58 %


CMXI's Growth Comparisons in II. Quarter 2026




Nuo Therapeutics reported top-line of $ 2 millions in the second quarter 2026, compare to $ 0 millions in the same quarter a year ago. Revenues in the Medical Laboratories industry grew by 11%, while the top-line in the Healthcare sector increased by 9.81%, and overall market improved by 3.91% from the second quarter 2025.

Sequentially company's Revenue were unchanged from the second quarter results. . Looking into annual growth, sales grew by % on average in last five years, while S & P 500's including only Businesses with the second quarter 2026 earnings reports, average yearly sales growth is 10.58%.


Growth Rates of CMXI's Income in the second quarter 2026


CMXI Operating Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Operating Income Change (Q2 MRQ) - -22.72 % 13.4 % 1.92 %
Sequential Operating Income Change (Q2 MRQ) - 11.28 % -6.06 % -3.12 %
Y / Y Operating Income Growth (Q2 TTM) - -28.07 % 16.8 % 8.76 %
Sequential Operating Income Growth (Q2 TTM) - -9.02 % 3.71 % 0.45 %
Operating Income 5 Year Avg. Change - 1.35 % 3.82 % 22.03 %


Income from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Income from Cont. Ops. Change (Q2 MRQ) - -17.45 % 25.33 % 5.16 %
Sequential Income from Cont. Ops. Change (Q2 MRQ) - 22.54 % -12.37 % -0.69 %
Y / Y Income from Cont. Ops. Change (Q2 TTM) - 24.57 % -1.37 % 2.11 %
Sequential Income from Cont. Ops. Change (Q2 TTM) - -4.99 % 6.07 % 1.23 %
Income from Cont. Ops. 5 Year Avg. Change - -16.01 % 1.89 % 40.7 %

CMXI Net Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Net Income Growth (Q2 MRQ) - -17.79 % 25.63 % 7.25 %
Q / Q Net Income Growth (Q2 MRQ) - 22.78 % -11.56 % -1.1 %
Y / Y Net Income Change (Q2 TTM) - -5.42 % -10.59 % 8.81 %
Sequential Net Income Change (Q2 TTM) - -6.86 % 5.56 % 1.71 %
Net Income 5 Year Avg. Growth - -13.88 % 6.74 % 39.75 %

CMXI's EPS Growth Rates


EPS from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS from Cont. Ops. Change (Q2 MRQ) - -34.09 % 25.33 % 5.16 %
Sequential EPS from Cont. Ops. Change (Q2 MRQ) - 19.84 % -12.37 % -0.69 %
Y / Y EPS from Cont. Ops. Change (Q2 TTM) 2700 % -63.02 % - -
Sequential EPS from Cont. Ops. Change (Q2 TTM) -3.45 % 2.01 % -91.85 % -
EPS from Cont. Ops. 5 Year Avg. Growth - -47.56 % 1.89 % 40.7 %



CMXI EPS Net Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS Net Growth (Q2 MRQ) - -34.36 % 25.63 % 40.7 %
Q / Q EPS Net Growth (Q2 MRQ) - 20.08 % -11.56 % -1.1 %
Y / Y EPS Net Change (for 12 months ending Q2 TTM) - -62.28 % -99.71 % 19.56 %
Sequential EPS Net Change (for 12 months ending Q2 TTM) -3.7 % 1.4 % - 0.5 %
EPS Net 5 Year Avg. Change - -13.88 % 6.74 % 39.75 %



Nuo Therapeutics reported bottom-line of $ -0.01 in the second quarter, compare to $ 0.00 in the same quarter a year ago. Medical Laboratories industry fell by -34.36%, while Healthcare sector increased by 25.63%, and overall market improved by 7.25%.

Sequentially company's EPS were unchanged from the second quarter results. . Looking into annual growth, income per share grew by % on average in the last five years, while the S & P 500's including only the businesses with the second quarter 2026 financial results, average yearly income per share growth is 39.75%.

CMXI Cash Flow Growth Rates


Free Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Free Cash Flow Change (Q2 MRQ) - 34.14 % 16.31 % -17.26 %
Sequential Free Cash Flow Change (Q2 MRQ) - 52.83 % 30.74 % 26.32 %
Y / Y Free Cash Flow Change (Q2 TTM) - -28.96 % 16.74 % -16.38 %
Sequential Free Cash Flow Change (Q2 TTM) - -0.94 % 3.38 % -5.36 %
Free Cash Flow 5 Year Avg. Change - 8.92 % 4.59 % -3.52 %

Net Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Net Cash Flow Change (Q2 MRQ) - -11.53 % - -95.91 %
Sequential Net Cash Flow Change (Q2 MRQ) - - - -
Y / Y Net Cash Flow Change (Q2 TTM) - 122.32 % -45.27 % -
Sequential Net Cash Flow Change (Q2 TTM) - -5.78 % -50.56 % -
Net Cash Flow 5 Year Avg. Change - 27.49 % -17.12 % -

Capital Expenditures Company Industry Sector S&P 500
Y / Y Capital Expenditures Change (Q2 MRQ) - 25.33 % 11.73 % 9.12 %
Sequential Capital Expenditures Change (Q2 MRQ) - 50.81 % 5.67 % 3.97 %
Y / Y Capital Expenditures Change (Q2 TTM) 21.19 % -10.33 % 20.81 % 3.91 %
Sequential Capital Expenditures Change (Q2 TTM) - 10.08 % 3.19 % 1.85 %
Capital Expenditures 5 Year Avg. Change - 11.67 % 8.86 % 6.52 %

Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Y/Y Annual




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.